LOTTE BIOLOGICS

Newsroom

Delivering the latest news
from LOTTE BIOLOGICS

Key visual

Event April 18, 2023

LOTTE BIOLOGICS Held a Ribbon Cutting Ceremony to Commemorate the Acquisition of Syracuse Plant

 

LOTTE BIOLOGICS Held a Ribbon Cutting Ceremony to Commemorate the Successful Acquisition of the Syracuse Plant

 

LOTTE BIOLOGICS announced that it held a Ribbon Cutting Ceremony on the 17th(local time in the U.S) to commemorate the successful acquisition of the Syracuse plant. The ceremony signifies a new beginning for their manufacturing plant in the U.S and aims to enhance a sense of belonging and morale among local employees, as well as strengthen the brand's position in the Syracuse area.

 

This ceremony, held at the Syracuse plant in the U.S., consisted of an opening video screening, greetings and company introductions, congratulatory remarks, ribbon cutting and unveiling ceremony, and commemorative photography. Including 500 local employees, the ceremony was attended by ▲LOTTE BIOLOGICS CEO, Richard Lee ▲LOTTE BIOLOGICS USA General Manager, Michael Hausladen ▲LOTTE BIOLOGICS Chief Operating Officer, Hyung-duk Yoo ▲LOTTE Corporation Chief Strategy Officer, Hun-ki Lee ▲Onondaga County Executive, Ryan McMahon ▲New York Governor, Kathy Hochul ▲Syracuse Mayor, Ben Walsh ▲Syracuse University Chancellor, Kent Syverud.

 

In particular, Dong-bin Shin, Chairman of LOTTE Group, leaved a message to the Syracuse employees through the opening video, and other congratulatory messages were sent by ▲Incheon Mayor, Jung-bok Yoo ▲IFEZ Commissioner Jin-yong Kim ▲Korea Biopharmaceutical Association President Jung-seok Lee. LOTTE BIOLOGICS has announced plans to establish a mega plant with a production capacity of 360,000 liters in South Korea, and to pursue bio-business in both South Korea and the United States.

 

Richard Lee, CEO of LOTTE BIOLOGICS, said "the Syracuse facility is more than just a production site; it is a place of great value that represents the invaluable efforts of our local employees and partner companies." "LOTTE BIOLOGICS will continue to strive to provide the best service to our customers and to supply the medicines that patients need."

 

Michael Hausladen, General Manager of LOTTE BIOLOGICS USA added: "Our Syracuse plant, which boasts a long history starting with the 1943 penicillin factory, has remained a leading bio-pharmaceutical production plant in the industry since the 2000s. We are very pleased to officially become a part of LOTTE and look forward to becoming the LOTTE BIOLOGICS North America Hub through active collaboration with local governments and partner companies"